Photo of Keyan Salari,  MD, PhD

Keyan Salari, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital


ksalari@mgh.harvard.edu

Keyan Salari, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Instructor, Surgery, Harvard Medical School
  • Assistant in Urology, Urology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am surgeon-scientist at Massachusetts General Hospital and Harvard Medical School focused primarily on translational research, applying cancer genomics and computational biology methods to advance precision cancer medicine in genitourinary malignancies. I have a clinical practice as a urologic oncologist in the MGH Department of Urology and MGH Cancer Center.

My research interests focus on leveraging a variety of genomic techniques and computational tools to gain insight into the pathobiology of prostate cancer, with the goal of improving early detection of clinically significant prostate cancer and distinguishing indolent from aggressive disease to guide treatment decisions.

Publications

Powered by Harvard Catalyst
  • Hanna N, Wszolek MF, Mojtahed A, Nicaise E, Wu B, Gelpi-Hammerschmidt FJ, Salari K, Dahl DM, Blute ML, Harisinghani M, Feldman AS. MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER. J Urol 2019. PubMed
  • Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. J Urol 2019; 201:721-727. PubMed
  • Wang Z, Hu L, Salari K, Bechis S, Ge R, Wu S, Rassoulian C, Pham J, Wu CL, Tabatabaei S, Douglas SW, Olumi AF. Androgenic to estrogenic switch in human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. J Pathol 2017. PubMed
  • Salari K, Spulak ME, Cuff J, Forster AD, Giacomini CP, Huang S, Ko ME, Lin AY, van de Rijn M, Pollack JR. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci U S A 2019; 109:E3196-205. PubMed